Three years in: How the IRA’s “Fair Pricing” has affected the biopharma development pipeline

PolicyBiotech

Oct 16

Written By Chris Morrison

IRADrug PricingPrice ControlsMedicareCMSEconomicsRA Capital AuthorRichard Xie

Chris Morrison

What you were reading - Rapport's top stories of 2025

© Copyright 2001-2026 RA Capital Management, L.P. This website is for informational purposes only and does not constitute an offer to provide investment advisory or other services by RA Capital Management, L.P. (“RA Capital”). Nothing contained on the website constitutes investment advice, and the views expressed should not be taken as advice to buy, sell, or hold any security or as an endorsement of any security or company. In preparing the information contained in this website, RA Capital has not taken into account the investment needs, objectives, and financial circumstances of any particular investor, and investments and companies referenced may not be suitable for all investors. Any views expressed were prepared based upon information available and believed to be reliable at the time such views were written. RA Capital makes no guarantees as to their accuracy or completeness. All information is subject to change and may quickly become unreliable for various reasons, including changes in market conditions or economic circumstances. By accessing this website, you agree not to copy, reproduce, republish, upload, post, transmit, alter, or distribute, in any way, content or materials from this website in any manner inconsistent with the purposes for which it is offered without the prior written consent of RA Capital.

Three years in: How the IRA’s “Fair Pricing” has affected the biopharma development pipeline

What you were reading - Rapport's top stories of 2025

The CDC once rescued my faith in science — who will rescue us now?